Use of Recombinant Activated Factor VII in Primary Postpartum Hemorrhage
Rattachement africain : gb, dk. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To collect data from nine European countries for cases of obstetric hemorrhage between 2000 and 2004 in which recombinant activated factor VII (rFVIIa) was used. METHODS: The cases were identified through national surveys. Standardized case report forms included sociodemographic details, past medical and obstetric history, and details of the progress and management of labor in which the postpartum hemorrhage occurred. Clinicians were asked to describe subjectively the effect of rFVIIa administration using two mutually exclusive categories: 1) bleeding reduced or 2) bleeding unchanged or worse. RESULTS: A total of 113 forms were returned (88%) with 97 (86%) classified as treatment, and 16 (14%) as "secondary prophylaxis." Clinicians noted improvements after a single dose for 80% of women in the treatment group, and for 75% in the secondary "prophylaxis" group. However, rFVIIa failed in 15 cases (13.8%). Few serious adverse events were noted related to rFVIIa administration; there were four cases of thromboembolism, one myocardial infarction, and one skin rash. CONCLUSION: Clinical reports and hematologic data suggest improvement for more than 80% of women after rFVIIa administration and few adverse effects. LEVEL OF EVIDENCE: II.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Use of Recombinant Activated Factor VII in Primary Postpartum Hemorrhage
- Date Crossref
- 01/12/2007
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Liverpool Division of Perinatal and Reproductive Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Novo Nordisk (Denmark) pays non établi dans la noticeEntreprise
-
Liverpool Women's Hospital pays non établi dans la noticeÉtablissement de santé
-
Supported by Novo Nordisk pays non établi dans la noticeInstitution
-
The authors thank all the clinicians who helped with the data collection pays non établi dans la noticeÉtablissement de santé
-
e-mail: [email protected] pays non établi dans la noticeInstitution
Division of Perinatal and Reproductive Medicine — University of Liverpool, Novo Nordisk (Denmark) et Liverpool Women's Hospital, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.